Over the past several months, Solid has continued to build its pipeline of therapeutic candidates that have the potential to address the full spectrum of Duchenne muscular dystrophy (DMD).
We are excited to announce a new collaboration with Dr. Dean Burkin of the University of Nevada and Strykagen to develop Galectin-1, a candidate that has the potential to aid in muscle regeneration and repair.
In DMD patients, the loss of dystrophin leads to an unstable muscle membrane, resulting in muscle damage, inflammation and degeneration. Galectin-1 is a protein found in muscle that has the potential to stabilize the muscle membrane through multiple novel pathways.
In preclinical studies, administration of the recombinant Galectin-1 protein has improved muscle integrity and strength. With further research, we believe that Galectin-1 has the potential to aid in muscle renewal and repair, increase blood supply and reduce inflammation. In addition, if successful Galectin-1 has the potential to complement future gene therapy approaches.
The Galectin-1 program is currently in preclinical development. Solid is excited to work with Dr. Burkin and his team to progress Galectin-1 through development and potentially limit the impact of dystrophin absence on muscle health and function.
VIEW OUR PIPELINE